Member Info for djwall1s

Not sure if this deal is with a real company or the 'airline' is a mock up one run by a parent to gather and record data but clearly Tally has got a partnership with someone up and running. Which hopefully bodes well.

It's not all bad though. I again draw your attention back to this that he posted in the Q and A:

"Evening xxxxxxx this b2B deal will see us implement the first use-case of tally where it solves a business problem, which is important as it shows the potential scope of building a better monetary system (rather than just a gold trading app, for example). There’ll be a 3-4 month lead time to go live, at which point we’ll announce the names. To provide some information, this use-case will see tally used as the basis of a frequent flyer points program for a new airline."

Well yes he is difficult to pin down. Because he broadly and consistently tells people that we are on the 'path' to IPO, makes a bunch of overtures and does interviews suggesting as such, but he cannot, frustratingly, ever give specific details. There's always a reason why an exact date to aim for can't be set. In this session he did talk about listing documents and what they need to do, which was a new development compared to past talk. But it all sounded like forward projections, not stuff he was actually currently getting on with. Yet he continues to make very public noises, including to the City, that the company will list 'this year.'

He needs to just get on with it.

For some reason some of the formatting (capital letters, certain words starred out) hasn't copied across here in Part 3. In the RNS itself the formatting looks to be in order.

part 3:

djt genetics programme

the genetics programme has delivered third generation seeds with at least 87.5 per cent. ****geneity. djt has created and documented the proprietary breeding protocols. djt intends to use these in partnership with a university genetics department to obtain access to third party grant funding to progress the programme to the sixth generation. following which, it would commence field trials with the resulting plants. the company will begin applying for government-backed grant funding opportunities as soon as the relevant annual grant calls are published. collectively, the impact of these decisions at djt plants has been a reduction of approximately £60,000 per month of operating expenses for the group.

ananda's ceo, melissa sturgess, commented: "the response to the announcement earlier this month that the endometriosis trial is being funded by nhs scotland has been extraordinarily encouraging. suddenly, we are experiencing awareness that a cannabinoid medicine has the potential to be a mainstream licenced medicine for this condition which affects more than 190 million women globally.

"the decision to pause medical cannabis flower operations at djt plants until there is a clear path to a profitable operation is the right one. it has resulted in the development of an innovative and cost-effective strategy to pursue the breeding programme with grant funding, which reduces group costs significantly and gives us the agility and flexibility required to properly pursue the clinical trials with the aim of nhs acceptance."

to stay abreast of the latest developments at ananda, we encourage you to follow our social media channels which are:

• instagram: htps://instagram.com/anandadevelopments?igshid=ymmymta2m2y=

• linkedin: htps://www.linkedin.com/company/anadevelopments/

• twitter: htps://twiter.com/anandaplc?s=21&t=9yeic_xycfzgdn7j26sfua

-ends-

the directors of the company accept responsibility for the contents of this announcement.

Part 2:

The endometriosis trial will assess the efficacy of MRX1 in the management of pain in 100 patients with endometriosis.

The CIPN (Chemotherapy Induced Peripheral Neuropathy) trial will assess the properties of MRX1 in affecting pain and mood in 100 patients who have CIPN.

The Company has commenced discussions with key clinical investigators for further RCT's using MRX1 for the treatment of other chronic inflammatory pain conditions, including a possible trial for fibromyalgia. NICE (The National Institute for Clinical Excellence) has made the clinical and cost effectiveness of cannabidiol for fibromyalgia a key recommendation for research. MRX1 and MRX2 cannabidiol medicines were launched in the UK as unlicenced medicinal products or specials at the end of July. Currently the oils are on the list of prescribable medicines of three private pain and medical cannabis clinics in the UK.

Ananda's objective is to obtain MHRA (Medicine and Healthcare products Regulatory Agency) licences for the medicines so that they can be prescribed in the NHS for the specific conditions which would likely result in wider use of the Company's cannabidiol medicines.

DJT medical cannabis ower, cultivation, and processing

DJT's 2023 medical cannabis cultivation trials are now complete. The trials have proven that the low capital, low operating cost cultivation model delivers premium quality medical cannabis flower. A large database of detailed standard operating procedures and protocols has now been developed. The next step towards producing medical cannabis flower for sale in the UK is to construct a GMP manufacturing facility. Ananda does not currently see sufficient demand for cannabis flower in the UK to justify the required capital expenditure so headcount at the Lincolnshire facility has been reduced. Ananda will continue to monitor market demand for cannabis flower before, subject to funding, progressing construction and licencing of a GMP facility. Ananda sees potential for the DJT facility to be used to supply cannabinoid APIs for its own MRX medicines.

Part 1:

Today 07:00

RNS Number : 8736K

Ananda Developments PLC

31 August 2023

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

Shareholder Update

Ananda Developments plc (AQSE:ANA), a company developing cannabinoid medicines for the treatment of chronic inflammatory pain conditions, provides the following corporate update.

Highlights

• The Chief Scientist Office, responsible for funding research in NHS Scotland, has been confirmed as the funder of the endometriosis randomised controlled trial ("RCT") using MRX1.

• Ananda is pursuing additional investigator led RCTs (Randomised Controlled Trials) evaluating MRX products in inflammatory pain conditions.

• Medical cannabis plant cultivation trials complete.

• Medical cannabis genetic breeding programme reached third generation of plants. Breeding protocol fully established.

• MRX1 and MRX2 cannabidiol medicines available for sale via UK based specials pharmacies.

MRX: cannabinoid unlicensed medicines

MRX1 has been selected to be used in two Phase 2 RCTs being conducted by leading clinicians from The University of Edinburgh. Drug supply agreements are being finalised and the MRX1 formulation is undergoing stability trials ahead of patient recruitment. Stability trials are being undertaken to align with the test method, outlined in the EU Pharmacopoeia, that will come into force in the EU in July 2024. Ananda expects these methods to apply in the UK at that time. The MRX medicines are being manufactured for the RCTs by a contract manufacturing organisation (CMO), using externally sourced GMP (Good Manufacturing Practice) grade active pharmaceutical ingredients (APIs).

He's generally always a good read on internal detail regarding corporate, what they're working on, the b2b and b2c stuff, some forward planning re: the tech, etc, but he's so difficult to pin down on listing that he undermines all the good stuff he says. I do give him credit for doing these sessions every month and he stays back to mop up holder questions after the hour is up. I just get no sense of urgency and dynamism with IPO as I do his plans to operate this as a tech platform.

I'm not going to stop posting IPO info that pertains to ALL shareholders. I bring across the points relating to IPO/relist and anything that injects an element of cheer or hope. We're all owed that, free. Not just some of us.

He reiterates:

"As I said in an earlier response this evening, we’re still pushing to see Tally listed by the end of this year or as close to it as possible. There are many factors to a successful IPO of Tally Central Ltd, and some of those are out of our control. What I said in the Marqeta interview is consistent with this."

No you can't remind me. I have been five years a slave to this company and so have you. There's no binding legal requirement not to reasonably share content to other shareholders and if it was so secret squirrel he wouldn't share it himself on a shareholder forum. We're not listed so it's hardly price sensitive.

"Evening xxxxxx we’re still pushing to see Tally listed by the end of this year or as close to it as possible. There are many factors to a successful IPO of Tally Central Ltd, and some of those are out of our control. What I said in the Marqeta interview is consistent with this."

Beige ho hum imo.

We'll see.

That is at least a bit more reassuring and notable than the opening statement which was typically beige in its non committal to listing, as expected.

"Evening xxxxxx this [new, first] b2B deal will see us implement the first use-case of tally where it solves a business problem, which is important as it shows the potential scope of building a better monetary system (rather than just a gold trading app, for example). There’ll be a 3-4 month lead time to go live, at which point we’ll announce the names. To provide some information, this use-case will see tally used as the basis of a frequent flyer points program for a new airline."

"Regarding IPO plans I am still unable at this stage to answer the two key IPO questions - when will the Company’s shares be trading again, and at what price? However we continue making progress...."

Blah blah blah blah blah blah blah ad infinitum.

Btw, not saying you -personally- have a perennial downer on this, just the general 'you' as in why would anyone in general continue to hold something with serious funding doubts? This makes no sense to me, if in doubt, get out is my motto.

I have a small, comfortable amount in this so am prepared to let it ride and just watch the progress. It won't be overnight, it'll take time and results-based effort.

If you have 'big negatives' why continue to invest in something you have a perennial downer on?

In any case, ANA has the rare distinction of a small company that is not endlessly and recklessly tapping up shareholders for funds, unlike others. They've managed to get themselves to serious clinical medical trials in Scotland with an eye on the NHS and without bothering shareholders much at all.

Yes, there are a lot of shares, yes, many are in sticky hands (there are pros and cons to that) and yes it's an incredibly boring and frustrating plod, yes it's annoying that we seem stuck on 0.0050p after years of progress . But the stickies are there because they've invested in the end goal. Is it worth a punt? You decide. Nobody has to sink much money in here, it's dirt cheap and not requiring of anyone putting a pound of flesh on the table. It's a company that you'd buy a few within your comfort zone, put away for a year at least and reassess. That's not to say things won't happen in the meantime. Good, sp driving things. And yes they may fundraise but again, it's not like, oh sheet, they're coming round with the begging bowl AGAIN. I used to invest in AIM miners and we were tapped up for brass nearly every 6 months, it was horrendous. It's a breeze here thus far in comparison .

I know it's hard for some to grasp, but with the lack of trust in conventional banking down at an all-time low, and some thoroughly, openly disreputable to downright evil behaviour among the big-name banks, Tally could unwittingly now find itself as a more important non-mainstream tool more than ever.

This could be something good, and big, if they get this show on the road and expand the team or allow themselves to be taken out by a player who could afford the progression and advancements that Tally just can't atm. There are still some fiddly tech issues and grumbles re: this app at times. But it's now a perfect storm of opportunity. I just hope he doesn't bypass it this time.

"This months Q&A will be held on Wednesday 30th July at 6pm." - Kris.

Obviously he means August. That message has just been posted. The date matches up with this Wednesday.

Sage advice from the other investor stuck in this share.

Very kind, bb, but I'm afraid I'd likely get sacked on day one, due to opposing views.

FG, come on, we can't keep putting this off because of the weather. Gold is back and forth all the time. Fundamentally it's THE proposition atm.